Life-science tools companies live or die by a workflow, not a molecule. A single-cell or spatial genomics experiment is a chain: you partition cells, you tag each one's contents with a unique barcode, you run all of it through a microfluidic chip, you sequence, and increasingly you image the sample to know where in a tissue each signal came from. 10x Genomics built a business around owning that chain, and its issued patent record reflects it — coverage distributed along every link rather than concentrated on one reagent. The week of 12 May 2026 added a chemistry tile to that chain.

On 12 May 2026, the U.S. patent office granted US12624475B1, "Capturing genetic targets using a hybridization approach." The abstract is compact:

Provided herein are methods of determining a location of an analyte using hybridization as a method for enhancing detection of the analyte.— Capturing genetic targets using a hybridization approach, US12624475B1

The phrase "determining a location of an analyte" is the tell: this is a spatial-genomics chemistry claim, where the goal is not just to detect a molecule but to know where it sat in a tissue. The issued claim text describes hybridizing a capture probe to the analyte and then extending it, which is the front-end capture step in a spatial assay. The grant's CPC tags — C40B 30/04 and C12N 15/1065 (combinatorial library screening and nucleic-acid processing) — place it squarely in the reagent-and-chemistry layer of the workflow. For a business reader, a granted capture-method claim matters because the capture step is where a competing spatial-genomics platform would also have to operate, so issued coverage there touches the part of the chain that is hardest to design around without affecting assay performance.

The estate runs the length of the instrument

The surrounding footprint is what makes this a coverage map, and 10x Genomics' grants reach far beyond chemistry into the hardware. At the partitioning step, US10428326B2 covers "droplet-based single cell barcoding" — the core method of isolating individual cells and tagging each one's contents, which is the conceptual heart of the company's single-cell products. Feeding that step, US10357771B2 covers a method of producing emulsions in which microfluidic-channel geometry is chosen to generate droplets of "a desired and predictable droplet size" — coverage on the physics of making uniform droplets at all. Around the reagents, US10343166B2 covers fluidic devices and methods for "encapsulating and partitioning reagents," the chemistry-delivery layer that gets the right reagents into each partition.

The hardware coverage is just as concrete. US12654168B2 covers "gaskets for the distribution of pressures in a microfluidic system" — an issued claim on a specific consumable component that controls how pressure reaches the channels of a microfluidic chip, about as far from a molecule as a genomics patent gets. And at the readout end, US12644837B2 covers an imaging system with an optical mounting plate, illumination assembly, and a heat sink that transfers heat away from the light sources via a working fluid — coverage on the optical instrument that images a spatial sample. Hybridization capture, droplet barcoding, emulsion generation, reagent encapsulation, microfluidic gaskets, imaging optics: the issued tiles trace the instrument from the chemistry in the tube to the camera over the slide.

The spread of CPC classes across these grants reinforces that the estate is genuinely multi-disciplinary rather than a single technology dressed up several ways. The chemistry grants sit in the C12 nucleic-acid classes (C12N 15/1065, the C12Q sequencing-and-detection family). The droplet and encapsulation grants reach into the B01L and B01F laboratory-apparatus and mixing classes — fluid-mechanics territory, not molecular biology. The gasket grant lives in B01L microfluidic-component classes. The imaging grant is classified in G01N optical-analysis classes and the H04N image-sensor classes that one would more often associate with a camera company. A patent estate that touches molecular biology, fluid dynamics, mechanical components, and imaging electronics is describing an instrument company, not a reagent supplier — and that breadth is itself the business point, because a competitor cannot route around the estate by simply substituting one chemistry; the coverage follows the workflow into the hardware and the optics as well.

What the workflow coverage buys

The business read on an end-to-end coverage map is about how many points of the workflow a competitor has to navigate. A granted claim is the enforceable part of an estate, and 10x Genomics holds issued claims at the partitioning step, the droplet-physics step, the reagent-delivery step, the chip-hardware step, the capture-chemistry step, and the imaging step. A rival building a competing single-cell or spatial platform encounters issued coverage at more than one link in its own chain — which is the kind of pressure that surfaces as licensing negotiations and the well-documented patent litigation that has run through the single-cell tools sector, rather than in any single headline. The newest grants — the 12 May 2026 capture method, the June 2026 gasket and detection-kit grants — indicate the estate is still adding coverage across both chemistry and hardware.

The standard caveats hold. Issued claims describe what was granted, not how broadly a court will construe a capture step or a gasket geometry, and not whether any particular claim survives a validity challenge — and the single-cell tools field is one where overlapping patents and active litigation mean a single grant maps one position, not the whole landscape. The older grants reflect filings from years ago and run on their own term clocks. But the pattern across 10x Genomics' record is unusually clear for a tools company: coverage distributed along the entire workflow, reagents through optics. The 12 May 2026 hybridization-capture grant is the newest tile, landing on the spatial-capture chemistry that the company's spatial products depend on.